Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 18/20 | 0.55 |
| ▸ | KDR | P35968 | 19/20 | 0.54 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12411563 | 0.87 | PDGFRA (0.66) | PDGFRAKDRBRAFMAPK14TNNI3K | |
| SCHEMBL12411348 | 0.87 | PDGFRA (0.55) | PDGFRAKDR | |
| SCHEMBL12411538 | 0.86 | PDGFRA (0.55) | PDGFRAKDRBRAFMAPK14TNNI3K | |
| SCHEMBL1892528 | 0.85 | PDGFRA (0.55) | PDGFRAKDRBRAFMAPK14TNNI3K | |
| SCHEMBL12411520 | 0.85 | PDGFRA (0.70) | PDGFRAKDR | |
| SCHEMBL1893404 | 0.84 | PDGFRA (0.77) | PDGFRAKDR | |
| SCHEMBL12411480 | 0.84 | PDGFRA (0.49) | PDGFRAKDRBRAFMAPK14TNNI3K | |
| SCHEMBL12411518 | 0.83 | PDGFRA (0.67) | PDGFRAKDR | |
| SCHEMBL12411484 | 0.81 | FLT3 (0.55) | KDR | |
| SCHEMBL12411510 | 0.79 | PDGFRA (0.52) | PDGFRAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973160-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20100197911-A1 | Nitrogen-Containing Aromatic Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-7612092-B2 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7253286-B2 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI CO., LTD (JP) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197911-A1 | Nitrogen-Containing Aromatic Derivatives | GNG2, GCG, FRG1 | PDGFRA 3131/4885KDR 2687/4885BRAF 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.